Arvinas - ARVN Stock Forecast, Price & News

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 5 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARVN shares.
View ARVN analyst ratings or view top-rated stocks.

18 analysts have issued 1 year target prices for Arvinas' shares. Their ARVN share price forecasts range from $27.00 to $95.00. On average, they predict the company's stock price to reach $68.75 in the next year. This suggests a possible upside of 151.6% from the stock's current price.
View analysts price targets for ARVN or view top-rated stocks among Wall Street analysts.

Arvinas' stock was trading at $34.21 at the beginning of the year. Since then, ARVN stock has decreased by 20.1% and is now trading at $27.32.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our ARVN earnings forecast.

Arvinas, Inc. (NASDAQ:ARVN) released its quarterly earnings data on Thursday, February, 23rd. The company reported ($1.56) EPS for the quarter, missing the consensus estimate of ($1.10) by $0.46. The firm earned $38 million during the quarter, compared to analysts' expectations of $35.32 million. Arvinas had a negative trailing twelve-month return on equity of 43.79% and a negative net margin of 228.19%. The company's quarterly revenue was up 32.4% on a year-over-year basis. During the same period last year, the company posted ($1.00) EPS.

ETFs with the largest weight of Arvinas (NASDAQ:ARVN) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), ALPS Medical Breakthroughs ETF (SBIO), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Virtus LifeSci Biotech Clinical Trials ETF (BBC), iShares U.S. Pharmaceuticals ETF (IHE), Principal Healthcare Innovators ETF (BTEC), BlackRock Future Health ETF (BMED) and Harbor Disruptive Innovation ETF (INNO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD).

(ARVN) raised $100 million in an initial public offering on Thursday, September 27th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray acted as the underwriters for the IPO.

Arvinas trades on the NASDAQ under the ticker symbol "ARVN."

Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ARVN stock can currently be purchased for approximately $27.32.

Arvinas (NASDAQ:ARVN) has a market capitalization of $1.46 billion and generates $131.40 million in revenue each year. The company earns $-282,500,000.00 in net income (profit) each year or ($5.32) on an earnings per share basis.

The company employs 280 workers across the globe.

Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The official website for the company is www.arvinas.com. The company can be reached via phone at (203) 535-1456 or via email at ir@arvinas.com.